Expression of prostaglandin PGE2 Receptors under conditions of aging and Stress and The protective effect of the EP2 agonist butaprost on Retinal Ischemia

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3238-3248

  Osborne, Neville N ^a   Li, Guang Yu ^b   Ji, Dan ^a   da Costa, Belmira L Andrade ^c   Fawcett, Rebecca J ^a   Kang, Kui Dong ^a   Rittenhouse, Kay D ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c Departamento de Fisiologia e Farmacologia   (Brazil)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTAPROST; CHOLINE ACETYLTRANSFERASE; DIMER; MESSENGER RNA; MONOMER; NERVE PROTEIN; NEURONAL NITRIC OXIDE SYNTHASE; OPTIC NERVE PROTEIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E3; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PRIMER DNA; PROSTAGLANDIN E; PROSTAGLANDIN E1; PROSTAGLANDIN EP2 RECEPTOR;

ACUTE STRESS; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRESS; CONTROLLED STUDY; MUELLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REPERFUSION; RETINA ISCHEMIA; THERAPY EFFECT; UPREGULATION; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG POTENTIATION; ELECTRORETINOGRAPHY; GENETICS; IMMUNOHISTOCHEMISTRY; INJECTION; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY; RETINA; RETINA DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITREOUS BODY; WESTERN BLOTTING; WISTAR RAT;

AGING; ALPROSTADIL; ANIMALS; BLOTTING, WESTERN; DNA PRIMERS; ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; INJECTIONS; NERVE TISSUE PROTEINS; NITRIC OXIDE SYNTHASE TYPE I; OXIDATIVE STRESS; PROSTAGLANDINS E, SYNTHETIC; RATS; RATS, WISTAR; RECEPTORS, PROSTAGLANDIN E; REPERFUSION INJURY; RETINA; RETINAL DISEASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VITREOUS BODY;

EID: 67649976991     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3185     Document Type: Article

References (66)

1. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21(2):195-218.
2. Araki E, Forster C, Dubinsky JM, Ross ME, Iadecola C. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke. 2001;32(10):2370-2375.
3. McCullough L, Wu L, Haughey N, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci. 2004; 24(1):257-268.
4. Bilak M, Wu L, Wang Q, et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol. 2004;56(2):240-248.
5. Choi JS, Kim HY, Chun MH, Chung JW, Lee MY. Expression of prostaglandin E2 receptor subtypes, EP2 and EP4, in the rat hippocampus after cerebral ischemia and ischemic tolerance. Cell Tissue Res. 2006;324(2):203-211.
6. Halenbeck JM, Leitch DR, Dutka AJ, Greenbaum LJ, McKee AE. Prostaglandin I2, indomethacin, and heparin promote postischemic neuronal recovery in dogs. Ann Neurol. 1982;12(2):145-156.
7. Sasaki T, Kitagawa K, Yamagata K, et al. Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab. 2004;24(1):107-113.
8. Iadecola C, Niwa K, Nogawa S, et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A. 2001;98(3):1294-1299.
9. Osborne NN, Lascaratos G, Bron AJ, Chidlow G, Wood JP. A hypothesis to suggest that light is a risk factor in glaucoma and the mitochondrial optic neuropathies. Br J Ophthalmol. 2006;90(2): 237-241.
10. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol. 2007; 52(suppl 2):162-173.
11. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193-1226.
12. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282(16):11613-11617
13. Okuda-Ashitaka E, Sakamoto K, Ezashi T, Miwa K, Ito S, Hayaishi O. Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype. J Biol Chem. 1996;271(49):31255-31261.
14. Hattori Y, Ohno T, Ae T, et al. Gastric mucosal protection against ethanol by EP2 and EP4 signaling through the inhibition of leukotriene C4 production. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):80-87.
15. Oldfield S, Grubb BD, Donaldson LF. Identification of a prostaglandin E2 receptor splice variant and its expression in rat tissues. Prostaglandins Other Lipid Mediat. 2001;63(4):165-173.
16. Boie Y, Stocco R, Sawyer N, et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997;340(2-3):227-241.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690.
18. Honda A, Sugimoto Y, Namba T, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem. 1993;268(11):7759-7762.
19. Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol. 1994;46(2):213-220.
20. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci. 2003;74(2-3):143-153.
21. Zhao C, Shichi H. Immunocytochemical localization of prostaglandin E2 receptor subtypes in porcine ocular tissues, II: nonuveal tissues. J Ocul Pharmacol Ther. 1995;11(3):437-445.
22. Biswas S, Bhattacherjee P, Paterson CA. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular tissues-a comparative immunohistochemical study. Prostaglandins Leukot Essent Fatty Acids. 2004;71(5):277-288.
23. Mukhopadhyay P, Bian L, Yin H, Bhattacherjee P, Paterson C. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest Ophthalmol Vis Sci. 2001;42(2):424-428.
24. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43(5):1475-1487.
25. Siminoff R, Bito, LZ. The effects of prostaglandins and arachidonic acid on the electroretinogram: evidence for functional cyclooxygenase activity in the retina. Curr Eye Res. 1981-1982; 1(11):635-642.
26. Najarian T, Hardy P, Hou X, et al. Preservation of neural function in the perinate by high PGE(2) levels acting via EP(2) receptors. J Appl Physiol. 2000;89(2):777-784.
27. Bazan NG. COX-2 as a multifunctional neuronal modulator. Nat Med. 2001;7(4):414-415.
28. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
29. Ju WK, Kim KY, Neufeld AH. Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia. Exp Eye Res. 2003;77(2):137-145.
30. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004;498(1-3):275-278.
31. Naveh N, Peer J, Bartov E, Weissman C. Argon laser irradiation of rabbits' eyes-changes in prostaglandin E2 levels. Prostaglandins. 1991;41(2):143-155.
32. Naveh N, Bartov E, Weissman C. Subthreshold argon-laser irradiation elicits a pronounced vitreal prostaglandin E2 response. Graefes Arch Clin Exp Ophthalmol. 1991;229(2):178-181.
33. Liu D, Wu L, Breyer R, Mattson MP, Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol. 2005;57(5):758-761.
34. Echeverria V, Clerman A, Doré S. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci. 2005; 22(9):2199-2206.
35. Akaike A, Kaneko S, Tamura Y, et al. Prostaglandin E2 protects cultured cortical neurons against N-methyl-D-aspartate receptormediated glutamate cytotoxicity. Brain Res. 1994;663(2):237-243.
36. Araki H, Ukawa H, Sugawa Y, Yagi K, Suzuki K, Takeuchi K. The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment Pharmacol Ther. 2000;14(suppl 1):116-124.
37. Ahmad AS, Zhuang H, Echeverria V, Doré S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma. 2006;23(12):1895-1903.
38. Takadera T, Yumoto H, Tozuka Y, Ohyashiki T. Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. NeurosciLett. 2002;317(2):61-64.
39. Takadera T, Shiraishi Y, Ohyashiki T. Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int. 2004;45(5):713-719.
40. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23(1):91-147.
41. Nash MS, Osborne NN. Assessment of Thy-1 mRNA levels as an index of retinal ganglion cell damage. Invest Ophthalmol Vis Sci. 1999;40(6):1293-1298.
42. Chidlow G, Casson R, Sobrado-Calvo P, Vidal-Sanz M, Osborne NN. Measurement of retinal injury in the rat after optic nerve transection: an RT-PCR study. Mol Vis. 2005;11:387-396.
43. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-685.
44. Hernandez MR, Pena JD. The optic nerve head in glaucomatous optic neuropathy. Arch Ophthalmol. 1997;115(3):389-395.
45. Tezel G. Oxidative stress in glaucomatous neurodegeneration; mechanisms and consequences. Prog Retinal Eye Res. 2006;25(5): 490-513.
46. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol. 2001;85(10):1252-1259.
47. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993;7(1):111-118.
48. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Doré S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 2005;1066(1-2):71-77.
49. Carrasco E, Werner P, Casper D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci Lett. 2008;441(1):44-49.
50. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103(2):147-166.
51. Gendron TF, Brunette E, Tauskela JS, Morley P. The dual role of prostaglandin E(2) in excitotoxicity and preconditioning-induced neuroprotection. Eur J Pharmacol. 2005;517(1-2):17-27.
52. Kawano T, Anrather J, Zhou P, et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med. 2006;12(2):225-229.
53. Carrasco E, Casper D, Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J Neurosci Res. 2007; 85(14):3109-3117.
54. Bringmann A, Pannicke T, Grosche J, et al. Müller cells in the healthy and diseased retina. Prog Retin Eye Res. 2006;25(4):397-424.
55. Block F, Schwarz M. The b-wave of the electroretinogram as an index for retinal ischemia. Gen Pharmacol. 1998;30(3):281-287.
56. Casson RJ, Chidlow G, Wood JP, Osborne NN. The effect of hyperglycemia on experimental retinal ischemia. Arch Ophthalmol. 2004;122(3):361-366.
57. Ji D, Li GY, Osborne NN. Nicotinamide attenuates retinal ischemia and light insults to neurones. Neurochem Int. 2008;52(4-5):786-798.
58. Zhang B, Rusciano D, Osborne NN. Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res. 2008;1198:141-152.
59. Katai N, Yoshimura N. Apoptotic retinal neuronal death by ischemia-reperfusion is executed by two distinct caspase family proteases. Invest Ophthalmol Vis Sci. 1999;40(11):2697-2705.
60. Caspases: key players in programmed cell death. Curr Opin Struct Biol. 2000;10(6):649-655.
61. Dawson VL, Dawson TM. Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr. 2004;36(4):287-294.
62. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversation in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci. 2004;25(5):260-264.
63. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6(5):513-519.
64. Nishiyama T, Nishukawa S, Hiroshi T, Tamai M. Müller cells in the preconditioned retinal ischemic injury rat. Tohoku J Exp Med. 2000;191(4):221-232.
65. Barnett NL, Osborne NN. Prolonged bilateral carotid artery occlusion induces electrophysiological and immunohistochemical changes to the rat retina without causing histological damage. Exp Eye Res. 1995;61(1):83-90.
66. Osborne NN, Li GY, Ji D, Mortiboys HJ, Jackson S. Light affects mitochondria to cause apoptosis to cultured cells: possible relevance to ganglion cell death in certain optic neuropathies. J Neurochem. 2008;105(5):2013-2028.